DEGAS, disease endophenotyping through graph and adjacency metrics: network biomarkers for Parkinson’s disease progression
Year: 2026
Type: article
Study design: Observational Study
Abstract: Parkinson’s disease (PD) progresses heterogeneously, yet no reliable biomarker stratifies patients for individualized care. We developed DEGAS, a machine learning framework applying functional connectivity to identify network-defined PD subtypes. Baseline functional MRI from 336 early-stage patients was stratified by suspected REM sleep behavior disorder (sRBD), a marker of aggressive disease. Adjacency matrices and graph theory metrics were integrated into classifiers, and predictions validated against three-year outcomes. Region-of-interest analyses showed no group differences in connectivity or topology. By contrast, models incorporating graph theory features achieved robust classification (balanced accuracy 0.91–0.93; MCC 0.61–0.78), outperforming adjacency-only models (balanced accuracy 0.79; MCC 0.52). Metrics that represented the basal ganglia-thalamic, temporal-limbic, and cerebello-cortical circuits were the strongest predictors. Patients classified as sRBD-positive showed worse motor outcomes, accelerated autonomic dysfunction, and higher rates of hallucinations, dyskinesias, and depression. The DEGAS framework defines a baseline network signature marking clinically distinct PD subgroups. External validation is required before clinical use is considered.
Source: npj Parkinson's Disease
Institutions: University of Florida Health, University of Florida
Language: English
Subfield: Cognitive Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,890
Funders: Michael J. Fox Foundation for Parkinson's Research, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Biogen, Teva Pharmaceutical Industries, Celgene, Jazz Pharmaceuticals, Neurocrine Biosciences, Verily Life Sciences, Aligning Science Across Parkinson’s, Voyager Therapeutics, Weston Family Foundation, Servier, H. Lundbeck A/S, Sun Pharma, Genentech, Johnson and Johnson, Allergan, Avid Radiopharmaceuticals
OpenAlex ID: W7235450947
